F11

F5A patient who is aged 1 year or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, F11or who is aged under 65 years and is at risk of developing medical complications from influenza, where—

a

the Department of Health has notified general medical practitioners that the influenza virus is circulating in the community;

b

the patient has an influenza-like illness; and

c

the patient can start therapy within 48 hours of the onset of symptoms.

F241A

Any patient suffering from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Secretary of State or F14are part of an antiviral distribution service provided by the Board, Public Health England or a Local Authority.

F12

F6A patient who is aged 1 year or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, where—

a

the Department of Health has notified general medical practitioners that the influenza virus is circulating in the community;

b

the patient has been exposed to an influenza-like illness through being in close contact with someone with whom he lives who is or has been suffering from an influenza-like illness;

c

the patient is not effectively protected by vaccination against influenza because—

i

he has not been vaccinated because vaccination is contraindicated;

ii

he has not been vaccinated since the previous influenza season;

iii

he has been vaccinated but it has yet to take effect; or

iv

he has been vaccinated but the vaccine is not well matched to the strain of influenza circulating in the locality in which the patient resides or is or has been present;

d

the patient lives in a residential care establishment and another resident or member of staff of the establishment has an influenza-like illness; and

e

the patient can start prophylaxis within 48 hours of exposure to an influenza-like illness.

F252A

Any patient at risk from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Secretary of State or F14are part of an antiviral distribution service provided by the Board, Public Health England or a Local Authority.

F31

F7A patient who is aged 5 years or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, F12or who is aged under 65 years and is at risk of developing medical complications from influenza, where—

a

the Department of Health has notified general medical practitioners that the influenza virus is circulating in the community;

b

the patient has an influenza-like illness; and

F8c

in the case of a patient—

i

who has attained the age of 5 years but not the age of 13 years, that patient can start therapy within 36 hours of the onset of symptoms; and

ii

who is aged 13 years or over, that patient can start therapy within 48 hours of the onset of symptoms.

F262

Any patient at risk of or suffering from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Secretary of State or F14are part of an antiviral distribution service provided by the Board, Public Health England or a Local Authority.

F161

The following patients with erectile dysfunction–

a

a man with erectile dysfunction who on 14th September 1998 was receiving a course of treatment under the Act, the National Health Service (Scotland ) Act 1978 M4 or the Health and Personal Social Services (Northern Ireland) Order 1972 M5for this condition with any of the following drugs—

• Alprostadil (Caverject), (MUSE), (Viridal)

• Apomorphine Hydrochloride (Uprima)

• Moxisylyte Hydrochloride (Erecnos)

• Sildenafil (Viagra)

• Tadalafil (Cialis)

• Thymoxamine

• Hydrochloride (Erecnos); or

b

a man who is not a national of an EEA State but who is the member of the family of such a national who has anenforceable Community right to be treated no less favourably than the national in the provision of medical treatmentand has erectile dysfunction and was being treated for that condition on 14th September 1998 with any of the drugs listed in sub-paragraph (a); or

c

a man who is a national of an EEA State who is entitled to treatment by virtue of Article 7(2) of Council Regulation 1612/68 M5as extended by the EEA Agreement or by virtue of any other enforceable Community right who has erectile dysfunction and was on 14th September 1998 receiving a course of treatment under a national health insurance system of an EEA State for this condition with any of the drugs listed in sub-paragraph (a); or

d

a man who is suffering from any of the following—

• diabetes

• multiple sclerosis

• parkinson’s disease

• poliomyelitis

• prostate cancer

• severe pelvic injury

• single gene neurological disease

• spina bifida

• spinal cord injury; or

e

a man who is receiving treatment for renal failure by dialysis; or

f

a man who has had the following surgery—

• prostatectomy

• radical pelvic surgery

• renal failure treated by transplantF17;

2

Any patient